➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 7,005,413

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 7,005,413
Title:Combination therapy for conditions leading to bone loss
Abstract: The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-.alpha. inhibitors, and serine protease inhibitors.
Inventor(s): Boyle; William J. (Moorpark, CA), Lacey; David Lee (Newbury Park, CA), Calzone; Frank J. (Westlake Village, CA), Chang; Ming-Shi (Tainan, TW)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:09/613,591
Patent Claims:see list of patent claims

Details for Patent 7,005,413

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept SYRINGE 103795 1998-11-02 ⤷  Free Forever Trial Amgen Inc. (Thousand Oaks, CA) 2015-12-22 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 1998-11-02 ⤷  Free Forever Trial Amgen Inc. (Thousand Oaks, CA) 2015-12-22 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.